Daiichi Sankyo (DSNKY) Projected to Post Earnings on Friday

Daiichi Sankyo (OTCMKTS:DSNKY) will likely be posting its results after the market closes on Friday, October 30th. Analysts expect the company to post earnings of $0.21 per share and revenue of $3.58 billion for the quarter. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. On average, analysts expect Daiichi Sankyo to post $0.93 EPS for the current fiscal year and $1.08 EPS for the next fiscal year.

Daiichi Sankyo Stock Down 7.9%

OTCMKTS DSNKY opened at $16.47 on Wednesday. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $26.80. The company has a fifty day simple moving average of $17.81 and a 200 day simple moving average of $17.76.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DSNKY shares. Zacks Research downgraded Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Daiichi Sankyo has an average rating of “Reduce”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.